Updates on hepato-renal syndrome

Journal of Anesthesia and Clinical Research

Volumn 4, Issue 9, 2013, Pages

  Fukazawa, Kyota ^a   Lee, H Thomas ^a  

^a College of Physicians and Surgeons of Columbia University ^*  (United States)

Author keywords

Acute kidney injury; Cirrhosis; Endothelial cell; Inflammation

Indexed keywords

EID: 84887161686     PISSN: None     EISSN: 21556148     Source Type: Journal    
DOI: 10.4172/2155-6148.1000352     Document Type: Review

References (85)

1. Nothnagel H (1899) Specielle Pathologie und Therapie. (2 edn) BiblioBazaar Vienna, pp. 63.
2. Flint A (1863) Clinical report on hydro-peritoneum, based on analysis of forty-six cases. Am J Med Sci 45: 306-339.
3. Hecker R, Sherlock S (1956) Electrolyte and circulatory changes in terminal liver failure. Lancet 271: 1121-1125.
4. Koppel MH, Coburn JW, Mims MM, Goldstein H, Boyle JD, et al. (1969) Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med 280: 1367-1371.
5. Schroeder ET, Shear L, Sancetta SM, Gabuzda GJ (1967) Renal failure in patients with cirrhosis of the liver. 3. Evaluation of intrarenal blood flow by para-aminohippurate extraction and response to angiotensin. Am J Med 43: 887-896.
6. Ginès P, Guevara M, Arroyo V, Rodés J (2003) Hepatorenal syndrome. Lancet 362: 1819-1827.
7. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, et al. (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 23: 164-176.
8. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V (2007) Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 56: 1310-1318.
9. European Association for the Study of the Liver (2010) EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 53: 397-417.
10. Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, et al. (1993) Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 105: 229-236.
11. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al.(1994) Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology, 1994. 20(6): 1495-501.
12. Ginès P, Schrier RW (2009) Renal failure in cirrhosis. N Engl J Med 361: 1279-1290.
13. Wadei HM, Gonwa TA (2013) Hepatorenal syndrome in the intensive care unit. J Intensive Care Med 28: 79-92.
14. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, et al. (1999) Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341: 403-409.
15. Quiroz ME, Flores YN, Aracena B, Granados-García V, Salmerón J, et al. (2010) Estimating the cost of treating patients with liver cirrhosis at the Mexican Social Security Institute. Salud Publica Mex 52: 493-501.
16. Levin J (2011) Disease burden in patients with chronic hepatitis C virus (HCV) infection in a United States (US) private health insurance claims database analysis from 2003 to 2010. 62th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco.
17. Everhart JE (1994) Digestive Diseases in the United States: Epidemiology and Impact. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington DC, US pp-1447.
18. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, et al. (2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122: 923-930.
19. Møller S, Hobolth L, Winkler C, Bendtsen F, Christensen E (2011) Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut 60: 1254-1259.
20. Sacerdoti D, Bolognesi M, Merkel C, Angeli P, Gatta A (1993) Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. Hepatology 17: 219-224.
21. Maroto A, Ginès A, Saló J, Clària J, Ginès P, et al. (1994) Diagnosis of functional kidney failure of cirrhosis with Doppler sonography: prognostic value of resistive index. Hepatology 20: 839-844.
22. Linas SL, Anderson RJ, Guggenheim SJ, Robertson GL, Berl T (1981) Role of vasopressin in impaired water excretion in conscious rats with experimental cirrhosis. Kidney Int 20: 173-180.
23. Bichet DG, Van Putten VJ, Schrier RW (1982) Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N Engl J Med 307: 1552-1557.
24. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, et al. (1988) Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8: 1151-1157.
25. Van Steenkiste C, Geerts A, Vanheule E, Van Vlierberghe H, De Vos F, et al. (2009) Role of placental growth factor in mesenteric neoangiogenesis in a mouse model of portal hypertension. Gastroenterology 137: 2112-2124.
26. Paternostro C, David E, Novo E, Parola M (2010) Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World J Gastroenterol 16: 281-288.
27. Langer DA, Shah VH (2006) Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. J Hepatol 44: 209-216.
28. Sumanovski LT, Battegay E, Stumm M, van der Kooij M, Sieber CC (1999) Increased angiogenesis in portal hypertensive rats: role of nitric oxide. Hepatology 29: 1044-1049.
29. Bellot P, Francés R, Such J (2013) Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int 33: 31-39.
30. Sugano S (1992) Endotoxin levels in cirrhotic rats with sterile and infected ascites. Gastroenterol Jpn 27: 348-353.
31. Heller J, Sogni P, Barrière E, Tazi KA, Chauvelot-Moachon L, et al. (2000) Effects of lipopolysaccharide on TNF-alpha production, hepatic NOS2 activity, and hepatic toxicity in rats with cirrhosis. J Hepatol 33: 376-381.
32. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, et al. (1999) Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 104: 1223-1233.
33. Frances R, Zapater P, Gonzalez-Navajas JM, Munoz C, Cano R, et al. (2008) Bacterial DNA in patients with cirrhosis and non-infected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology 47: 978-985.
34. Tazi KA, Moreau R, Hervé P, Dauvergne A, Cazals-Hatem D, et al. (2005) Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling. Gastroenterology 129: 303-314.
35. Fernández J, Navasa M, Planas R, Montoliu S, Monfort D, et al. (2007) Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 133: 818-824.
36. Stadlbauer V, Wright GA, Banaji M, Mukhopadhya A, Mookerjee RP, et al. (2008) Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 134: 111-119.
37. Ruiz-del-Arbol L, Urman J, Fernández J, González M, Navasa M, et al. (2003) Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 38: 1210-1218.
38. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Ginès P, et al. (2005) Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 42: 439-447.
39. Arroyo V, Fernandez J, Ginès P (2008) Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 28: 81-95.
40. Alqahtani SA, Fouad TR, Lee SS (2008) Cirrhotic cardiomyopathy. Semin Liver Dis 28: 59-69.
41. Cooper MS, Stewart PM (2003) Corticosteroid insufficiency in acutely ill patients. N Engl J Med 348: 727-734.
42. Tsai MH, Peng YS, Chen YC, Liu NJ, Ho YP, et al. (2006) Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology 43: 673-681.
43. Fernández J, Escorsell A, Zabalza M, Felipe V, Navasa M, et al. (2006) Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. Hepatology 44: 1288-1295.
44. Helwig F, Schutz CA (1935) further contribution to the liver-kidney syndrome. J. Lab. and Clin. Med 21: 264.
45. Wilensky A (1939) Occurrence, Distribution and Pathogenesis of So-Called Liver Death and/or the Hepatorenal Syndrome. Arch Surg 38: 625-691.
46. Boyer TD, Zia P, Reynolds TB (1979) Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 77: 215-222.
47. Hampel H, Bynum GD, Zamora E, El-Serag HB (2001) Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol 96: 2206-2210.
48. Guevara M, Fernández-Esparrach G, Alessandria C, Torre A, Terra C, et al. (2004) Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology 40: 646-651.
49. Cárdenas A, Ginès P (2001) Pathogenesis and treatment of fluid and electrolyte imbalance in cirrhosis. Semin Nephrol 21: 308-316.
50. Møller S, Hansen EF, Becker U, Brinch K, Henriksen JH, et al. (2000) Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 20: 51-59.
51. Davenport A, Ahmad J, Al-Khafaji A, Kellum JA, Genyk YS, et al. (2012) Medical management of hepatorenal syndrome. Nephrol Dial Transplant 27: 34-41.
52. Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, et al. (2000) Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 33: 43-48.
53. Nazar A, Pereira GH, Guevara M, Martín-Llahi M, Pepin MN, et al. (2010) Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 51: 219-226.
54. Wadei HM (2012) Hepatorenal syndrome: a critical update. Semin Respir Crit Care Med 33: 55-69.
55. Somberg KA, Lake JR, Tomlanovich SJ, LaBerge JM, Feldstein V, et al. (1995) Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology 21: 709-716.
56. Quiroga J, Sangro B, Núñez M, Bilbao I, Longo J, et al. (1995) Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology 21: 986-994.
57. Ng CK, Chan MH, Tai MH, Lam CW (2007) Hepatorenal syndrome. Clin Biochem Rev 28: 11-17.
58. Wanner GA, Ertel W, Müller P, Höfer Y, Leiderer R, et al. (1996) Liver ischemia and reperfusion induces a systemic inflammatory response through Kupffer cell activation. Shock 5: 34-40.
59. Tsung A, Hoffman RA, Izuishi K, Critchlow ND, Nakao A, et al. (2005) Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol 175: 7661-7668.
60. Levy RM, Mollen KP, Prince JM, Kaczorowski DJ, Vallabhaneni R, et al. (2007) Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol 293: R1538-1544.
61. Tanaka Y, Maher JM, Chen C, Klaassen CD (2007) Hepatic ischemia-reperfusion induces renal heme oxygenase-1 via NF-E2-related factor 2 in rats and mice. Mol Pharmacol 71: 817-825.
62. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251.
63. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, et al. (2000) High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192: 565-570.
64. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, et al. (2005) The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 201: 1135-1143.
65. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, et al. (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279: 7370-7377.
66. Davis CL, Gonwa TA, Wilkinson AH (2002) Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part I. Liver Transpl 8: 91-109.
67. Lee HT, Park SW, Kim M, D'Agati VD (2009) Acute kidney injury after hepatic ischemia and reperfusion injury in mice. Lab Invest 89: 196-208.
68. Teoh NC, Farrell GC (2003) Hepatic ischemia reperfusion injury: pathogenic mechanisms and basis for hepatoprotection. J Gastroenterol Hepatol 18: 891-902.
69. Sutton TA, Mang HE, Campos SB, Sandoval RM, Yoder MC, et al. (2003) Injury of the renal microvascular endothelium alters barrier function after ischemia. Am J Physiol Renal Physiol, 285: F191-F198.
70. Molitoris BA, Sandoval R, Sutton TA (2002) Endothelial injury and dysfunction in ischemic acute renal failure. Crit Care Med 30: S235-240.
71. Okusa MD (2002) The inflammatory cascade in acute ischemic renal failure. Nephron 90: 133-138.
72. Klausner JM, Paterson IS, Goldman G, Kobzik L, Rodzen C, et al. (1989) Postischemic renal injury is mediated by neutrophils and leukotrienes. Am J Physiol 256: F794-802.
73. Park SW, Chen SW, Kim M, D'Agati VD, Lee HT (2010) Selective intrarenal human A1 adenosine receptor overexpression reduces acute liver and kidney injury after hepatic ischemia reperfusion in mice. Lab Invest 90: 476-495.
74. Park SW, Chen SW, Kim M, Brown KM, D'Agati VD, et al. (2010) Protection against acute kidney injury via A(1) adenosine receptor-mediated Akt activation reduces liver injury after liver ischemia and reperfusion in mice. J Pharmacol Exp Ther 333: 736-747.
75. Park SW, Chen SW, Kim M, D'Agati VD, Lee HT (2009) Human activated protein C attenuates both hepatic and renal injury caused by hepatic ischemia and reperfusion injury in mice. Kidney Int 76: 739-750.
76. Park SW, Chen SW, Kim M, D'Agati VD, Lee HT (2009) Human heat shock protein 27-overexpressing mice are protected against acute kidney injury after hepatic ischemia and reperfusion. Am J Physiol Renal Physiol 297: F885-894.
77. Park SW, Kim M, Chen SW, Brown KM, D'Agati VD, et al. (2010) Sphinganine- 1-phosphate protects kidney and liver after hepatic ischemia and reperfusion in mice through S1P1 receptor activation. Lab Invest 90: 1209-1224.
78. Park SW, Chen SW, Kim M, Brown KM, Kolls JK, et al. (2011) Cytokines induce small intestine and liver injury after renal ischemia or nephrectomy. Lab Invest 91: 63-84.
79. Park SW, Kim M, Brown KM, D'Agati VD, Lee HT (2011) Paneth cell-derived interleukin-17A causes multiorgan dysfunction after hepatic ischemia and reperfusion injury. Hepatology 53: 1662-1675.
80. Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, et al. (2011) Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 60: 702-709.
81. Salerno F, Cazzaniga M, Merli M, Spinzi G, Saibeni S, et al. (2011) Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol 55: 1241-1248.
82. Randers E, Erlandsen EJ (1999) Serum cystatin C as an endogenous marker of the renal function--a review. Clin Chem Lab Med 37: 389-395.
83. Bennett M, Dent CL, Ma Q, Dastrala S, Grenier F, et al. (2008) Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 3: 665-673.
84. Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, et al. (2012) Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci 57: 2362-2370.
85. Platt JF, Ellis JH, Rubin JM, Merion RM, Lucey MR (1994) Renal duplex Doppler ultrasonography: a noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease. Hepatology 20: 362-369.